We are live on ! Find out more
NARI

Inari Medical, Inc. Common Stock

Delisted

NARI was delisted on the 18th of February, 2025.

240 hedge funds and large institutions have $3.4B invested in Inari Medical, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 109 increasing their positions, 66 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 17

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

65% more repeat investments, than reductions

Existing positions increased: 109 | Existing positions reduced: 66

12% more call options, than puts

Call options by funds: $11.6M | Put options by funds: $10.4M

10% more capital invested

Capital invested by funds: $3.1B → $3.4B (+$301M)

6% more funds holding

Funds holding: 227240 (+13)

Holders
240
Holders Change
+13
Holders Change %
+5.73%
% of All Funds
4.13%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.09%
New
32
Increased
109
Reduced
66
Closed
17
Calls
$11.6M
Puts
$10.4M
Net Calls
+$1.2M
Net Calls Change
+$6.78M
Name Holding Trade Value Shares
Change
Change in
Stake
KeyBank National Association
176
KeyBank National Association
Ohio
$260K -$84.5K -1,135 -24%
DFCM
177
Dark Forest Capital Management
Puerto Rico
$253K +$258K +3,468 +18,253%
UBS Group
178
UBS Group
Switzerland
$250K +$9.46K +127 +4%
EGM
179
Engineers Gate Manager
New York
$247K +$21.7K +291 +9%
Truist Financial
180
Truist Financial
North Carolina
$234K +$2.23K +30 +0.9%
Mackenzie Financial
181
Mackenzie Financial
Ontario, Canada
$231K -$8.26K -111 -3%
William Blair & Company
182
William Blair & Company
Illinois
$227K
SCA
183
Snowden Capital Advisors
New York
$224K +$230K +3,094 New
PAMS
184
Pictet Asset Management (Switzerland)
Switzerland
$215K +$220K +2,960 New
LFAS
185
Level Four Advisory Services
Texas
$213K -$222K -2,984 -50%
MLICM
186
Metropolitan Life Insurance Company (MetLife)
New York
$211K
XT
187
XTX Topco
Cayman Islands
$204K -$105K -1,416 -34%
Osaic Holdings
188
Osaic Holdings
Arizona
$183K +$45.1K +606 +32%
GWM
189
Geneos Wealth Management
Colorado
$181K
FF
190
FourThought Financial
Florida
$170K
AssetMark Inc
191
AssetMark Inc
California
$133K +$55.6K +747 +69%
US Bancorp
192
US Bancorp
Minnesota
$117K -$15.5K -208 -11%
Nisa Investment Advisors
193
Nisa Investment Advisors
Missouri
$106K +$28.9K +388 +39%
PNC Financial Services Group
194
PNC Financial Services Group
Pennsylvania
$100K +$13.7K +184 +16%
BFEC
195
Benjamin F. Edwards & Company
Missouri
$69K -$5.58K -75 -7%
IA
196
IFP Advisors
Florida
$68K +$1.79K +24 +2%
APA
197
American Portfolios Advisors
New York
$67.5K -$15.3K -205 -18%
MA
198
MUFG Americas
New York
$58K
Canada Pension Plan Investment Board
199
Canada Pension Plan Investment Board
Ontario, Canada
$50K +$14.9K +200 +41%
DWMG
200
DB Wealth Management Group
California
$44K

NARI Hedge Fund Activity: Q3 2022 in Review

240 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Inari Medical, Inc. Common Stock (NARI) for Q3 2022, worth a combined $3.4B — up 9.7% from $3.1B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new NARI positions and 17 closed out — a net gain of 15 holders — while 109 added to existing stakes and 66 trimmed.

The largest buyer was BlackRock, adding an estimated $63.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $97M.

  • 240 institutional investors held Inari Medical, Inc. Common Stock (NARI) as of Q3 2022, up from 227 in Q2 2022.
  • Funds reported $3.4B of Inari Medical, Inc. Common Stock stock for Q3 2022, up 9.7% quarter-over-quarter.
  • 32 funds opened new Inari Medical, Inc. Common Stock positions in Q3 2022 and 17 closed out, a net change of +15 holders.
  • The largest Inari Medical, Inc. Common Stock buyer in Q3 2022 was BlackRock, an estimated $63.9M added.
  • The largest Inari Medical, Inc. Common Stock seller in Q3 2022 was T. Rowe Price Associates, an estimated $97M sold.

Based on aggregated 13F filings for Q3 2022.